Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.

Pharmacogenomics - 1 Oct 2011

Tzvetkov Mladen V, Behrens Gerrit, O'Brien Valerie P, Hohloch Karin, Brockmöller Jürgen, Benöhr Peter

Abstract excerpt

AIM: We investigated whether genetic polymorphisms may contribute to the interpatient variability of cisplatin-induced nephrotoxicity. PATIENTS & METHODS: Polymorphisms in the candidate genes GSTM1, GSTT1, OCT1, OCT2, LARP2, ERCC1, XRCC1 and EPO were analyzed for associations with nephrotoxicity in 79 cancer patients receiving cisplatin-containing chemotherapy. RESULTS: Higher cisplatin dose was associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Genetic Association Studies

Share to Glomerular Filtration Rate

Share to Haplotypes

Share to Homozygote

Share to Kidney

Source

Identifiers

PMID: 21902499
DOI: 10.2217/pgs.11.93

Genes

ERCC1
EPO
GSTM1
GSTT1
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.PMID 21902499Read ↗

Pharmacogenomics of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients of Different Ethnic OriginsSemantic proximity Read ↗

Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer PatientsSemantic proximity Read ↗

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Semantic proximity Read ↗

Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving CisplatinSemantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients.Semantic proximity Read ↗

Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma.Semantic proximity Read ↗

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.Semantic proximity Read ↗

Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.Semantic proximity Read ↗

Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.Semantic proximity Read ↗

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.